A recent report published by Infinium Global Research on next-generation sequencing market provides in-depth analysis of segments and sub-segments in the global as well as regional next-generation sequencing market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional next-generation sequencing market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global next-generation sequencing market.
The next-generation sequencing (NGS) market report gives a wide-ranging overview of the industry trends, market growth factors, impediments, and the promising future opportunities till the year 2032. The market is driven by the development of sequencing technologies that provide higher throughput, better accuracy, and lower costs; these technologies include the ones based on sequencing by synthesis, nanopore, and semiconductor sequencing. The report divides the market into product and service categories such as sequencing instruments, reagents and consumables, bioinformatics and data analysis services. Consumables are the largest market share holders as they are constantly needed during the sequencing process, which is also supported by continuous innovation and new user-friendly solutions. Technology segmentation points out targeted resequencing as the biggest application segment, while whole-genome and whole-exome sequencing are growing the fastest. Clinical uses, mostly in oncology and personalized medicine, are the main demand drivers, complemented by increasing application in drug discovery, genetic testing, and farming. North America regions have the largest market share worldwide owing to its well-funded research institutions, advanced technology manufacturers, and supportive healthcare infrastructure. Asia-Pacific is the quickest growing region with huge investments in genomics and better healthcare access. Europe on the other hand is retaining its position due to strict regulations and well-developed research framework.
The next-generation sequencing (NGS) market is heavily supported by public sector investments and initiatives, as evidenced by government data and public research funding. The U.S. National Institutes of Health (NIH), the principal public funding source, granted an estimated $1.2 billion annually for genomics research involving NGS technologies. Genomics England's 100,000 Genomes Project set aside £300 million (around $370 million) to cover the sequencing of patient genomes through the British National Health Service (NHS) aimed at developing personalized medicine. In parallel, Genome Canada proposed $200 million to improve sequencing capacity in the health and research sectors. These government-sponsored projects not only provide financial support for the technological upgrade, data infrastructure and workforce training, but also are instrumental in the development, acceptance and ramping up of NGS platforms. The public funding of this magnitude and the national-scale projects create a global market that is predicted to grow at a CAGR of about 14-18%, which is a clear indication of the continuous support to speed up genomic research and its clinical application.
The market for next-generation sequencing services is quite large and is likely to continue growing at a fast pace. Presently, it is estimated to be worth around USD 12.2 billion and is expected to reach USD 87.5 billion by the year 2035, mainly due to the high demand in diagnostics, drug discovery, and biomarker identification. Consumables and reagents together make up a significant portion of the revenue simply because of the recurring needs in sequencing processes.
Sequencing by synthesis (SBS) has been the most popular platform for a long time, and it has the largest share of the market, which is about 65%, because of its ability to perform various applications, such as whole genome and targeted resequencing, with great accuracy and reliability. New developments like long-read sequencing, single-cell RNA sequencing, and nanopore technology are making a lot of noise and helping to create a wider range of applications. The merging of AI and machine learning is changing the landscape of data analytics by making it faster, more accurate, and better at correcting mistakes.
The clinical diagnostics market sector is the largest application segment, with the main focus on oncology and rare disease research, which account for nearly 91% of the clinical NGS data analysis needs. Other applications that are gaining traction are drug discovery, reproductive health, agriculture, and microbial research, all of which indicate the ever-expanding footprint of NGS from human healthcare to other areas like biological and environmental sciences.
NGS data analysis has hospitals and clinical laboratories as its main end users in precision medicine, oncology diagnostics, and genetic counseling. Furthermore, academic and government research centers are making extensive use of NGS for genomics and translational research. The biopharma industry is undergoing a shift, where NGS is being incorporated more and more into drug development, target identification, and pharmacogenomics, resulting in a higher demand for not only sequencing services but also the platforms that produce them.
The global next-generation sequencing market is largely dominated by North America, which takes up about 50% share and this has been aided by the strong healthcare infrastructure, research funding, and precision medicine technologies that are already in place. Europe is responsible for one-fourth of the market, which is the result of extensive genomics research programs and strict regulatory standards. Asia-Pacific is the fastest-growing regional segment with an expected CAGR of more than 18%, factors that stimulate it include: the increasing governmental support for genomics, large heterogeneous populations, and better access to healthcare. China, India, Japan, and South Korea are the key nations driving the growth of the region. The other regions like Latin America, the Middle East, and Africa, although they are developing, are doing that by means of public health initiatives and partnerships e.g., collaborations between sequencing companies and Africa CDC to improve genomic surveillance in Africa. The movements in these different regions indicate how much public funding and infrastructure matter when it comes to the adoption and advancement of NGS technologies globally.
The new developments in the field of next-generation sequencing (NGS) during the year 2025 are mainly due to the introduction of new technology, forming of strategic alliances, and the opening up of new applications.
The most notable among these is Illumina, which has founded a new division called BioInsight that will concentrate on the use of data analysis combined with artificial intelligence and multiomic datasets to speed up the process of drug target discovery and deepen biological understanding.
Roche, on the other hand, has set up its sequencing-by-expansion (SBX) technology, which is a novel platform that takes advantage of synthetic molecules to reduce the sequencing time from days to hours.
Thermo Fisher Scientific has won three R&D 100 awards for various innovations, one of which is the Stellar Mass Spectrometer that offers ten times more sensitivity in the analysis of biomarkers, thereby helping the development of therapeutics in precision medicine faster.
Oxford Nanopore Technologies has been able to report a large increase in revenue for the first half of 2025 due to the implementation of operational excellence initiatives and the signing of new partnerships. Most recently, their collaboration with Cepheid for automatic infectious disease sequencing solutions is an example of commercial momentum and technological maturity.
Recent developments in the field of NGS reflect the fact that leading companies are using innovative sequencing chemistries along with the integrated data analytics and the strategic collaborations created to satisfy the evolving research and clinical demands, which will eventually lead to wider adoption of NGS technologies and precision healthcare advancements.
| Report Coverage | Details |
|---|---|
| Market Size in 2023 | USD 8.14 Billion |
| Market Size by 2032 | USD 38.62 Billion |
| Growth Rate from 2024 to 2032 | CAGR of 20.93% |
| Largest Market | North America |
| No. of Pages | 300 |
| Market Drivers |
|
| Market Segmentation | By Product & Service, By Technology, By Application, and By End User |
| Regional Scope | North America, Europe, Asia Pacific, and RoW |
The report on global next-generation sequencing market provides a detailed analysis of segments in the market based on Product & Service, Technology, Application, and End User.
· Sequencing Instruments
· Consumables & Reagents
· Data Analysis Software & Bioinformatics Services
· Sample Collection & Extraction Kits
· Sequencing by Synthesis (SBS)
· Semiconductor-based Sequencing
· Nanopore Sequencing
· Single-molecule Real-time (SMRT) Sequencing
· Synthetic Long-read Sequencing (SLS)
· Clinical Diagnostics
· Precision Medicine & Pharmacogenomics
· Reproductive Health & Prenatal Testing
· Agricultural Genomics
· Microbiome & Metagenomics Research
· Basic Genomic & Functional Research
· Hospitals & Diagnostic Labs
· Pharmaceutical & Biotechnology Companies
· Academic & Government Research Institutes
· Agricultural and Environmental Research Centers
· Direct-to-Consumer Genomics Services
· Illumina, Inc.
· Thermo Fisher Scientific, Inc.
· Pacific Biosciences (PacBio)
· Oxford Nanopore Technologies
· BGI Group
· Hoffmann-La Roche Ltd. (Roche)
· QIAGEN
· Agilent Technologies
· GenScript Biotech Corporation (GenScript)
· Swift Biosciences Inc.
The report provides deep insights into demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the next-generation sequencing market. Moreover, the study highlights current market trends and provides forecasts from 2024-2032. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.